Since the first description of epileptic encephalopathy associated with neurodevelopmental disorders related to SCN8A mutation, the clinical picture of patients suffering from this disease is now quite well-defined. SCN8A mutations (MIM # 614558 EIEE-13) have been identified in approximately 1% of patients with Epileptic Encephalopathy [1] .
Recently various authors have reported patients (18 affected members of 4 unrelated families) carrying an autosomal dominant heterozygous SCN8A mutation and a milder phenotype expression with normal cognitive and neurological development, mild pharmacoresponsive epilepsy and movement disorders [2, 3] .
Like other mutations in the Na+ channel, the phenotypic spectrum of this mutation thus seems to be expanding.
Our patient is a 6-year-old girl with a family history of epilepsy: the maternal grandmother had suffered from generalized epilepsy, the first cousin of the paternal grandmother suffered from generalized seizures in childhood and suspended the drug during adolescence; no movement disorders are reported. She was born of healthy non-consanguineous parents by normal delivery at term following an uneventful pregnancy: neonatal weight: 2780 g, head circumference: 32 cm. The girl presents normal intellectual and behavioral development. Since birth an upper limb tremor (especially noticeable upon waking and when excited) was evident; the child also presented hypotonia, ligamentous laxity and a slight delay in motor acquisitions (independent walking at 18 months), unstable postural control and ataxia. The child was hospitalized at age 4 1 / 2 months for the occurrence of a cluster of short seizures characterized by hypotonia, loss of consciousness and cyanosis. These seizures were diagnosed as "Benign focal epilepsy in infancy with midline spikes and waves during sleep".
During the hospitalization she underwent long-lasting polygraphic-EEG in which a different episode was recorded upon awakening. This episode was characterized by staring, widespread bilateral symmetric hypertonic posturing and myoclonic tremor, not accompanied by critical electroencephalographic paroxysms (Fig. 1A, B) . The child was subjected to many exams for suspicious "Near Miss" episodes: routine blood tests, metabolic tests (blood and urine amino acids, urine organic acids, ammonia), Holter-ECG and pHmetry: all negative; cerebral TC was normal. In the followup she had febrile seizures and at the age of 10 months she had an epileptic status characterized by impaired consciousness, staring and cyanosis, which was resolved with an acute administration of Phenobarbital and Pyridoxine; successively she was treated with Carbamazepine (CBZ), resulting in complete control of the crisis. Seizures reappeared at the age of 2 1 / 2 years due to the reduction of CBZ in an attempt to replace it with Levitiracetam; the seizures were characterized by stiffening and version of the head to the left, lasting a few seconds.
Repeated wakefulness EEG were normally organized, free of epileptic abnormalities; during sleep, however, tests recorded low amplitude spikes followed by one or more bell-shaped slowwaves, isolated or in short sequences on the vertex with a tendency to involve the central regions bilaterally (Fig. 1C) .
The cerebral MRI was normal. Now she is seizure-free under low doses of CBZ; her cognitive development is normal (cognitive evaluation -WPPSI-III scaleperformed at age 5 showed TIQ = 99; VQI = 108; PQI = 93) with good verbal communication skills, adequate attention spans and normal visuo-spatial functions. The neurological exam is normal except for ataxia and postural tremor.
Due to the presence of early seizures (completely controlled by treatment with CBZ), associated with movement disordersmyoclonic tremor and ataxia -the child was submitted to a genetic test with the use of a diagnostic panel of epileptic encephalopathies. A heterozygous de novo mutation of the SCN8A gene was found, with nucleotide substitution of c.3943G > A (1315 p.Val Met), which alters an evolutionary conserved amino acid. The mutation residue is located in the domain III S4/S5 intracellular linker which includes several previously identified pathogenic mutations [1] .
We report here an additional case of SCN8A gene mutation associated with early onset, well-controlled benign epilepsy, normal cognitive development, ataxia and myoclonic tremor. Given the type of seizures and their early onset, the good response to a Na+ channel blocker and the very early onset of the movement disorders -we believe that this gene mutation is responsible for the pathology that affected the child.
In the literature two other cases with the same mutation have been reported: a child with the same de novo mutation described by Trump [4] and another case listed in the "Decipher database". Both patients have an epileptic encephalopathy. Our patient's milder phenotype could be caused by a modifier effect, possibly a mutation in another gene or a mosaicism. We have no definite explanation for this fact and we think that further genetic testing would be needed to explain the mild phenotype of our case.
Anand describes the case of a father and son with pharmacologically-controlled focal seizures, absence of clinical and neurological impairment associated with the mutation c.5630A > G; p. Asn1877Ser (described as responsible for epileptic encephalopathy) of SCN8A gene. The authors attribute the favorable clinical evolution of their cases to the possible presence of somatic mosaicism -excluded in the father -or the presence of the association with other genetic variants [2] .
Gardella describes 16 members of 3 families with normal cognitive development, epileptic phenotype of BIFS type with the association in some of the members of episodes of paroxysmal dyskinesia/choreo-athetosis, attributed to a missense mutation c.4447G > A; p.E1483K. The authors consider that this mutation may be a new gene responsible for BFIS/ICCA pathology and that this can be an expansion of the clinical spectrum of SCN8A mutation [3] . Table 1 summarizes the clinical features of patients with both severe and mild phenotype. We underline that the patients described with SCN8A mutation and benign evolution are similar to our case: onset of seizures in the first year of life, seizures' type, good response to drugs blocking the Na+ channel, no relapse after drug withdrawal, normal cognitive development and normal neuroradiological examination, association with different types of Nav1.6 subunit, encoded by the gene SCN8A, possesses unique biophysical properties, which make it a critical mediator of neuronal excitability. Heterozygous missense mutations of the gene are reported in children with early epileptic encephalopathy, in which the mutation causes gain-of-function so that it promotes neuronal hyperexcitability. Gardella suggests that small gain-of function fits with mild phenotype [3] . Heterozygous mutation is linked to gain-of-function of the gene, for this reason Carbamazepine, a sodium channel blocker, is an effective drug for the treatment of the epileptic seizures [1] .
In view of the polymorphism of seizures, epileptic syndromes, their evolution, the occurrence of rare reports of SUDEP, the variability of cognitive development and the inconstant association of different types of movement disorders, it could be difficult to predict the full range of the spectrum of the clinical features. The detailed description of our case should contribute to enlarging the description of the clinical features of SCN8A mutation and to recommending the deepening of genetic investigations to identify other genes that could contribute to modulate its expression.
We would like to suggest a targeted genetic evaluation in childhood epilepsies with early onset, (even benign) when associated with a movement disorder.
